COVID-19 和大流行期间的新指南影响了妇科癌症的治疗途径，导致治疗方案出现了延误和修改。本研究的目的是确定 COVID-19 大流行对芬兰主要妇科癌症护理中心之一坦佩雷大学医院的影响。我们的回顾性登记研究包括 909 名新发妇科癌症病例（子宫癌、宫颈癌、 2018 年 3 月 17 日至 2022 年 3 月 15 日期间转诊至坦佩雷大学医院妇科肿瘤门诊。根据转诊时间，患者被分为两个不同的组： 感染新冠肺炎之前的时间（3 月 17 日） ，2018年至2020年3月15日）以及新冠疫情期间（2020年3月16日至2022年3月15日）。对这些群体的患者特征、不同癌症类型和阶段、症状和治疗方法进行了比较。在 COVID-19 大流行期间，患者普遍出现癌症症状的时间更长 (p< 0.003)，并且更有可能超重 (p = 0.035）。改进后的多学科团队会议为患者在新冠肺炎期间提供了更快的首次干预途径 (p<0.05)。在新冠疫情期间，我们看到了向非手术首次干预和非治疗目的的微小转变，但多学科团队的治疗计划在这两个时期大多都相应地实施了。新发妇科癌症病例数没有减少，两组的一年总生存率保持不变。总体而言，COVID-19 大流行并没有显着改变坦佩雷大学医院妇科癌症护理的治疗途径。新患者和接受治疗的数量保持相对稳定。在新冠疫情期间，转诊到癌症治疗的速度显着加快，这可能与 2021 年初制定的多学科团队方案的变化相混淆。© 2024 作者。斯堪的纳维亚妇产科学报，约翰·威利 (John Wiley) 出版

COVID-19 and new guidelines during the pandemic affected the gynecologic cancer treatment pathways, resulting in recorded delays and modifications in the treatment protocols. The aim of this study was to determine the impact of the COVID-19 pandemic in one of the major gynecologic cancer care centers in Finland, Tampere University Hospital.Our retrospective register study included 909 patients that were new gynecologic cancer cases (uterine, cervical, vulvar, vaginal, or ovarian) referred to the Tampere University Hospital Gynecologic Oncology Outpatient Clinic between March 17th, 2018, and March 15th, 2022. The patients were divided into two separate groups depending on their time of referral: time before COVID (March 17th, 2018, to March 15th, 2020), and during COVID (March 16th, 2020, to March 15th, 2022). These groups were compared in terms of patient characteristics, different cancer types and stages, symptoms, and treatment methods.During the COVID-19 pandemic, patients generally suffered from cancer symptoms longer (p < 0.003) and were more likely to be overweight (p = 0.035). The improved multidisciplinary team meeting gave the patients a faster route to their first intervention during COVID (p < 0.05). An insignificant shift toward nonsurgical first interventions and non-curative intent was seen during COVID, but the multidisciplinary team treatment plans were mostly implemented accordingly on both eras. No decrease was seen in the number of new gynecologic cancer cases, and the one-year overall survival remained the same in both groups.Overall, the COVID-19 pandemic did not significantly alter treatment pathways in gynecologic cancer care at Tampere University Hospital. The number of new patients and given treatments remained relatively stable. During COVID, access from referral to cancer treatment was significantly accelerated, which is likely confounded by changes to the multidisciplinary team protocol made in early 2021.© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).